Magnus Persson biography
Dr. Magnus Modee Persson M.D. Ph.D. serves as Independent Director of the Company. Dr. Persson has served as an Associate Professor in Physiology at the Karolinska Institutet since September 1994. Dr. Persson has served as a practicing pediatrician at CityAkuten and Barnsjukhuset Martina in Stockholm, Sweden since December 2012. Previously, Dr. Persson served as a Partner at HealthCap, a Swedish-based venture capital firm, from January 1996 through December 2009, and as a Managing Partner at The Column Group, a San Francisco-based venture capital firm, from January 2010 through November 2011. Dr. Persson co-founded Aerocrine AB, a medical technology company in 1994. Dr. Persson has also served on the boards of Galecto AB, a biotechnology company, since January 2013, Gyros Protein Technologies AB, a provider of peptide synthesis and bioanalytical tools since March 2012, ADDI Medical AB, a healthcare IT-software company, since October 2015, Immunicum AB, a biotechnology company, since December 2015, and Attgeno AB, a biotechnology company, since January 2018. Dr. Persson received his M.D. and Ph.D. in physiology from the Karolinska Institutet. Our Board believes that Dr. Persson’s extensive experience in medicine, life sciences and biotechnology financing and his experience founding and leading public biotechnology and medical technology companies make him a valuable member of our Board who will assist in the development of our growth strategy and business plans.
What is the salary of Magnus Persson?
As the Independent Director of Cerecor Inc, the total compensation of Magnus Persson at Cerecor Inc is $91,880. There are 3 executives at Cerecor Inc getting paid more, with Joseph Miller having the highest compensation of $1,170,600.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Magnus Persson?
Magnus Persson is 60, he's been the Independent Director of Cerecor Inc since 2012. There are 3 older and 6 younger executives at Cerecor Inc. The oldest executive at Cerecor Inc is Sol Barer, 72, who is the Chairman of the Board.
What's Magnus Persson's mailing address?
Magnus's mailing address filed with the SEC is C/O CERECOR INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE, MD, 20850.
Insiders trading at Cerecor Inc
Over the last 9 years, insiders at Cerecor Inc have traded over $0 worth of Cerecor Inc stock and bought 18,463,844 units worth $43,946,959 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Capital, Llc Armistice Capi.... On average, Cerecor Inc executives and independent directors trade stock every 19 days with the average trade being worth of $601,142. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 16 August 2021, trading 50,000 units of CERC stock currently worth $138,000.
What does Cerecor Inc do?
Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.
What does Cerecor Inc's logo look like?
Cerecor Inc executives and stock owners
Cerecor Inc executives and other stock owners filed with the SEC include:
-
Joseph Miller,
Director -
Jamie Harrell,
Chief Commercial Officer -
Phil Gutry,
Independent Director -
Magnus Persson,
Independent Director -
Gilla Kaplan,
Independent Director -
Steven Boyd,
Independent Director -
Suzanne Bruhn,
Director -
Jeff Wilkins,
Chief Development Officer -
Garry Neil,
Chief Scientific Officer -
Christopher Sullivan,
Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer -
Michael Cola,
Chief Executive Officer, Director -
Sol Barer,
Chairman of the Board -
Thomas H Aasen,
Director -
Mariam E Morris,
Chief Financial Officer -
Ronald Marcus,
Chief Medical Officer -
John Joseph Kaiser,
Chief Business Officer -
Eugene A Bauer,
Director -
Robert Jr. Moscato,
Director -
Peter Greenleaf,
Director -
Keith Schmidt,
Director -
Pericles Calias,
Chief Scientific Officer -
Matthew V Phillips,
Chief Commercial Officer -
Randal Jones,
Director -
Patrick J Crutcher,
VP, Business Development -
Robert Jr.Lrs International...,
-
Randal Fremantle, Llc Jones,
-
Capital, Llc Boyd Steven Ar...,
-
Simon Pedder,
Executive Chairman of the Bd -
Uli Hacksell,
Director -
Tree Partners Iv, L.P.Atp I...,
-
David M Mott,
10% owner -
Behshad Sheldon,
Director -
Anthony A. Jr. Florence,
10% owner -
Krishna Kittu Kolluri,
10% owner -
Peter W. Sonsini,
10% owner -
Harry R Weller,
10% owner -
Blake M Paterson,
CEO and President -
Forest Baskett,
10% owner -
Ravi Viswanathan,
10% owner -
M James Barrett,
10% owner -
Scott D Sandell,
10% owner -
Enterprise Associates 14, L...,
-
Bioventures V, L.P.Mpm Asse...,
-
Peter J Barris,
10% owner -
Patrick J Kerins,
10% owner -
Isaac Blech,
Director -
James Archie Jr Harrell,
Chief Commercial Officer -
Schond L. Greenway,
CFO